{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT05162326",
      "OrgStudyIdInfo": {
        "OrgStudyId": "BC101-C01"
      },
      "Organization": {
        "OrgFullName": "Bright Cell, Inc.",
        "OrgClass": "INDUSTRY"
      },
      "BriefTitle": "BC-101 in Treatment of Nasolabial Fold Wrinkles",
      "OfficialTitle": "A Phase 1/2 Study of the Safety and Efficacy of BC-101 in Treatment of Nasolabial Fold Wrinkles Via Subcutaneous/Intradermal Injection"
    },
    "StatusModule": {
      "StatusVerifiedDate": "December 2021",
      "OverallStatus": "Not yet recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "July 1, 2022",
        "StartDateType": "Anticipated"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "June 30, 2023",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "June 30, 2023",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "December 4, 2021",
      "StudyFirstSubmitQCDate": "December 4, 2021",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "December 17, 2021",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "December 4, 2021",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "December 17, 2021",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Bright Cell, Inc.",
        "LeadSponsorClass": "INDUSTRY"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes",
      "IsFDARegulatedDrug": "Yes",
      "IsFDARegulatedDevice": "No",
      "IsUSExport": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "This is an open-label, single-arm, dose-escalating study to evaluate the safety and tolerability of BC-101 administered via subcutaneous/intradermal injection in the treatment of moderate to severe nasolabial folds."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Moderate to Severe Nasolabial Fold Wrinkles"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Sequential Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "9",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "BC-101",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "BC-101 will be injected at the dose of 0.1 mL per linear centimeter along the nasolabial fold, up to 2 mL in total volume for each side of the nasolabial folds.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: BC-101"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "BC-101",
            "InterventionDescription": "Human umbilical cord tissue derived mesenchymal stem cells (hUC-MSC) suspension at concentration of 2, 4, or 6 million cells/mL.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "BC-101"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Safety and tolerability of BC-101 injection",
            "PrimaryOutcomeDescription": "Incidence of any treatment-emergent adverse events",
            "PrimaryOutcomeTimeFrame": "12 weeks after injection"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Changes in wrinkle severity assessment from baseline",
            "SecondaryOutcomeDescription": "Each of the bilateral nasolabial fold wrinkles at rest will be evaluated using the 6-point ordinal Lemperle Wrinkle Severity Scale.",
            "SecondaryOutcomeTimeFrame": "6 weeks, 12 weeks and 26 weeks after injection"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nSubjects who are in general good health condition.\nSubjects who have moderate to extremely deep bilateral nasolabial fold wrinkles, as documented by a score of 3 or greater on the six-point Evaluator Wrinkle Severity Assessment scale (0-5).\nSubjects who are dissatisfied with both nasolabial fold wrinkles based on a score of -1 or -2 on the Subject Wrinkle Assessment Scale (-2 to +2).\nSubjects who voluntarily adhere to the research procedures and ensure good compliance during the research period.\nSubjects who fully understand the research nature of this study and sign the informed consent.\n\nExclusion Criteria:\n\nSubjects who have an active cutaneous infection on the face.\nSubjects with existing malignant neoplasm.\nSubjects with persistent pre-cancerous lesions (e.g., actinic keratosis).\nSubjects who have active dermal diseases, inflammation, or any related disease.\nSubjects who have cosmetic or surgical treatment on nasolabial fold area in 3 months before the study (including laser, chemical peels, fillers, botulinum toxin).\nSubjects who are pregnant, breastfeeding, or whose urinary pregnancy test is positive before participation in the study.\nSubjects who are allergic to low-molecular-weight heparin sodium or human albumin.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "40 Years",
      "MaximumAge": "80 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Jennifer Wang",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "949-333-3636",
            "CentralContactEMail": "jenniferw@brightcellinc.com"
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 21, 2022"
    }
  }
}